Switch theme
Sign up to access all valuation multiples
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
1976
168
Last FY Revenue $9.5M
Last FY EBITDA $0.7M
$15.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Etropal achieved revenue of $9.5M and an EBITDA of $0.7M.
Etropal expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Etropal valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $9.5M | XXX | XXX | XXX |
| Gross Profit | XXX | $2.9M | XXX | XXX | XXX |
| Gross Margin | XXX | 30% | XXX | XXX | XXX |
| EBITDA | XXX | $0.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 8% | XXX | XXX | XXX |
| EBIT | XXX | $0.3M | XXX | XXX | XXX |
| EBIT Margin | XXX | 3% | XXX | XXX | XXX |
| Net Profit | XXX | $0.1M | XXX | XXX | XXX |
| Net Margin | XXX | 1% | XXX | XXX | XXX |
| Net Debt | XXX | $2.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of June 30, 2025, Etropal's stock price is BGN 4 (or $3).
Etropal has current market cap of BGN 21.0M (or $12.7M), and EV of BGN 26.0M (or $15.7M).
See Etropal trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15.7M | $12.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of June 30, 2025, Etropal has market cap of $12.7M and EV of $15.7M.
Etropal's trades at 1.6x EV/Revenue multiple, and 21.0x EV/EBITDA.
Equity research analysts estimate Etropal's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Etropal's P/E ratio is not available.
See valuation multiples for Etropal and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.7M | XXX | $12.7M | XXX | XXX | XXX |
| EV (current) | $15.7M | XXX | $15.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 21.0x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 47.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 236.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 50.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEtropal's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $15K for the same period.
Etropal's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Etropal's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Etropal and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $15K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma Trading | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Etropal acquired XXX companies to date.
Last acquisition by Etropal was XXXXXXXX, XXXXX XXXXX XXXXXX . Etropal acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Etropal founded? | Etropal was founded in 1976. |
| Where is Etropal headquartered? | Etropal is headquartered in Bulgaria. |
| How many employees does Etropal have? | As of today, Etropal has 168 employees. |
| Is Etropal publicy listed? | Yes, Etropal is a public company listed on BUL. |
| What is the stock symbol of Etropal? | Etropal trades under ETR ticker. |
| When did Etropal go public? | Etropal went public in 2007. |
| Who are competitors of Etropal? | Similar companies to Etropal include e.g. Ansell, Polymed, Farmaceutica Remedia, Sopharma. |
| What is the current market cap of Etropal? | Etropal's current market cap is $12.7M |
| Is Etropal profitable? | Yes, Etropal is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
